Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NEUP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $12.72M
- EPS (TTM)
- -$2.07
- Dividend yield
- None
- 52-week range
- 2.26 – 5.53
- Day range
- 2.27 – 2.38
- Volume / Avg
- 55.96K / 26.53K
- Beta
- —
- Shares outstanding
- 5.41M
52-week range
NEUP stock today
Neuphoria Therapeutics (NEUP) closed at $2.35 on Nov 20, up 1.29% (+$0.03), versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 55.96K shares, a sign of unusually heavy trading. At this level, NEUP sits near the bottom of its 52-week range of $2.26 to $5.53: 57.5% below the high, set on May 22, 2026 and 4.0% above the low.
NEUP is down 39.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 47.3%. Neuphoria Therapeutics has posted a net loss over the last twelve months (EPS of -$2.07), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Neuphoria Therapeutics
Company profileNeuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Spyridon Papapetropoulos M.D., Ph.D.
- Headquarters
- Millis, MA
- Employees
- 1
- IPO year
- 2021
- Website
- neuphoriatx.com
Financial highlights
Full financialsIn fiscal 2026, Neuphoria Therapeutics generated $1.2 million in revenue, down 92.5% from fiscal 2025, the first decline in the 4 years shown. Neuphoria Therapeutics reported a net loss of $13.5 million, compared with a loss of $369,632 a year earlier. Operating margin was -1401.1%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue | $1.17M | $15.65M | — | — |
| Growth | -92.50% | — | — | — |
| Net income | $-13.45M | $-369.63K | $-15.49M | $-21.38M |
| EPS (diluted) | $-3.06 | $-0.23 | $-18.62 | $-0.02 |
Analyst forecast
ForecastConsensus (1 analysts)
none
- Strong buy 0
- Buy 0
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.26 vs —
NEUP news
All NEUP newsNeuphoria Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALLRAllarity Therapeutics Inc. | 0.785 | -9.25% | $12.56M | vs NEUP |
| MCRBSeres Therapeutics Inc. | 1.24 | -6.77% | $12.64M | vs NEUP |
| MIRAMIRA Pharmaceuticals Inc. | 0.291 | -20.84% | $12.23M | vs NEUP |
| BOLTBolt Biotherapeutics Inc. | 4.91 | -2.96% | $12.80M | vs NEUP |
| TVRDTvardi Therapeutics Inc. | 0.9893 | +4.57% | $13.22M | vs NEUP |
| ACTUActuate Therapeutics Inc. | 0.2253 | +5.38% | $13.60M | vs NEUP |
| BYSIBeyondSpring Inc. | 0.33 | -24.49% | $13.66M | vs NEUP |
| CTXRCitius Pharmaceuticals Inc. | 0.5085 | +2.27% | $13.96M | vs NEUP |
Indexes, lists and sector
Neuphoria Therapeutics stock FAQ
What is Neuphoria Therapeutics's stock price today?
NEUP last traded at $2.35 as of Nov 20, 4:00 PM EST, up 1.29% on the day. Prices are delayed at least 15 minutes.
Does Neuphoria Therapeutics pay a dividend?
No. Neuphoria Therapeutics does not currently pay a regular cash dividend.
Who is Neuphoria Therapeutics's CEO?
Dr. Spyridon Papapetropoulos M.D., Ph.D. is the chief executive officer of Neuphoria Therapeutics Inc., which has about 1 employees.
Has NEUP ever split its stock?
Yes. The most recent NEUP stock split was a 1-for-12 split on Dec 24, 2024.
What is the NEUP 52-week high?
The 52-week high for NEUP is $5.53 and the 52-week low is $2.26. The stock is currently 57.5% below its high.